{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:19:18Z","timestamp":1780373958395,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The description of every possible adverse effect or event related to vaccines is mandatory during the ongoing worldwide COVID-19 vaccination program. Although cases of cutaneous varicella\u00a0zoster virus (VZV) reactivation after COVID-19 vaccination have been increasingly reported in literature and database sets, a description of VZV-induced neurological disease (VZV-ND) is still lacking. In the present study, we retrospectively evaluated patients admitted to our clinic and diagnosed with VZV-ND during the COVID-19 vaccination campaign (January\u2013April 2021) and in the same months in the previous two\u00a0years. We identified three patients with VZV-ND after COVID-19 vaccination and 19 unvaccinated VZV-ND cases as controls. In the case\u2013control analysis, the two groups showed no difference in clinical features, results of diagnostic investigations, and outcome. Thus, VZV\u00a0reactivation with neurological involvement might be a possible event triggered by COVID-19 vaccination, but the benefit following COVID-19 vaccination overcomes significantly the potential risk associated with a VZV\u00a0reactivation.<\/jats:p>","DOI":"10.1007\/s00415-021-10849-3","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T06:02:22Z","timestamp":1635746542000},"page":"1751-1757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Varicella\u00a0zoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study"],"prefix":"10.1007","volume":"269","author":[{"given":"Samir","family":"Abu-Rumeileh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Still","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2737-7495","authenticated-orcid":false,"given":"Makbule","family":"Senel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"10849_CR1","unstructured":"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/vaccines-covid-19\/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section"},{"key":"10849_CR2","unstructured":"https:\/\/vaers.hhs.gov\/data.html"},{"key":"10849_CR3","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ana.26065","volume":"89","author":"AL Goss","year":"2021","unstructured":"Goss AL, Samudralwar RD, Das RR, Nath A (2021) ANA investigates: neurological complications of COVID-19 vaccines. Ann Neurol 89:856\u2013857. https:\/\/doi.org\/10.1002\/ana.26065","journal-title":"Ann Neurol"},{"key":"10849_CR4","unstructured":"https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions"},{"key":"10849_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20639","author":"A Catal\u00e0","year":"2021","unstructured":"Catal\u00e0 A, Mu\u00f1oz-Santos C, Galv\u00e1n-Casas C et al (2021) Cutaneous reactions after SARS-COV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.20639","journal-title":"Br J Dermatol"},{"key":"10849_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/B978-0-444-53488-0.00012-2","volume":"123","author":"D Gilden","year":"2014","unstructured":"Gilden D, Nagel MA, Cohrs RJ (2014) Varicella-zoster. Handb Clin Neurol 123:265\u2013283. https:\/\/doi.org\/10.1016\/B978-0-444-53488-0.00012-2","journal-title":"Handb Clin Neurol"},{"key":"10849_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/WCO.0000000000000092","volume":"27","author":"MA Nagel","year":"2014","unstructured":"Nagel MA, Gilden D (2014) Neurological complications of varicella zoster virus reactivation. Curr Opin Neurol 27:356\u2013360. https:\/\/doi.org\/10.1097\/WCO.0000000000000092","journal-title":"Curr Opin Neurol"},{"key":"10849_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/QCO.0000000000000647","volume":"33","author":"MA Nagel","year":"2020","unstructured":"Nagel MA, Niemeyer CS, Bubak AN (2020) Central nervous system infections produced by varicella zoster virus. Curr Opin Infect Dis 33:273\u2013278. https:\/\/doi.org\/10.1097\/QCO.0000000000000647","journal-title":"Curr Opin Infect Dis"},{"issue":"9155","key":"10849_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S0140-6736(99)00623-6","volume":"353","author":"R Walter","year":"1999","unstructured":"Walter R, Hartmann K, Fleisch F et al (1999) Reactivation of herpesvirus infections after vaccinations? Lancet 353(9155):810. https:\/\/doi.org\/10.1016\/S0140-6736(99)00623-6","journal-title":"Lancet"},{"issue":"6","key":"10849_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3390\/vaccines9060572","volume":"9","author":"M Psichogiou","year":"2021","unstructured":"Psichogiou M, Samarkos M, Mikos N, Hatzakis A (2021) Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines (Basel) 9(6):572. https:\/\/doi.org\/10.3390\/vaccines9060572","journal-title":"Vaccines (Basel)"},{"key":"10849_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00549-1","author":"J Diez-Domingo","year":"2021","unstructured":"Diez-Domingo J, Parikh R, Bhavsar AB et al (2021) Can COVID-19 increase the risk of herpes zoster? A narrative review. Dermatol Ther (Heidelb). https:\/\/doi.org\/10.1007\/s13555-021-00549-1","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10849_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab345","author":"V Furer","year":"2021","unstructured":"Furer V, Zisman D, Kibari A et al (2021) Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keab345","journal-title":"Rheumatology (Oxford)"},{"key":"10849_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin MJ, Bijl M et al (2015) Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines 3:109\u2013120. https:\/\/doi.org\/10.1177\/2051013615599151","journal-title":"Ther Adv Vaccines"},{"key":"10849_CR14","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/infdis\/jiz652","volume":"222","author":"HF Tseng","year":"2020","unstructured":"Tseng HF, Bruxvoort K, Ackerson B et al (2020) The epidemiology of herpes zoster in immunocompetent, unvaccinated adults \u226550 years old: incidence, complications, hospitalization, mortality, and recurrence. J Infect Dis 222:798\u2013806. https:\/\/doi.org\/10.1093\/infdis\/jiz652","journal-title":"J Infect Dis"},{"key":"10849_CR15","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"10849_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"key":"10849_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"issue":"40","key":"10849_CR18","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1016\/j.vaccine.2021.08.088","volume":"39","author":"T Brosh-Nissimov","year":"2021","unstructured":"Brosh-Nissimov T, Sorek N, Yeshayahu M et al (2021) (2021) Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19. Vaccine 39(40):5729\u20135731. https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.088","journal-title":"Vaccine"},{"key":"10849_CR19","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y et al (2021) Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 385:1078\u20131090","journal-title":"N Engl J Med"},{"key":"10849_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMcp013211","volume":"347","author":"JW Gnann Jr","year":"2002","unstructured":"Gnann JW Jr, Whitley RJ (2002) Clinical practice. Herpes zoster. N Engl J Med 347:340\u2013346. https:\/\/doi.org\/10.1056\/NEJMcp013211","journal-title":"N Engl J Med"},{"key":"10849_CR21","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1161\/STROKEAHA.120.031293","volume":"51","author":"S Sacco","year":"2020","unstructured":"Sacco S, Ricci S, Ornello R et al (2020) Reduced admissions for cerebrovascular events during COVID-19 outbreak in Italy. Stroke 51:3746\u20133750. https:\/\/doi.org\/10.1161\/STROKEAHA.120.031293","journal-title":"Stroke"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10849-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10849-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10849-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T16:15:29Z","timestamp":1647965729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10849-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10849"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10849-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"15 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The local ethics committee of the University of Ulm approved this study (ethics approval number 236\/21).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}